Myeloid Sarcoma in Patients with RUNX1/RUNX1T1 Positive AML and a c-kit Mutation / 대한내과학회지
Korean Journal of Medicine
;
: 517-525, 2011.
Article
in Korean
| WPRIM
| ID: wpr-164061
ABSTRACT
t (8;21)(q22;q22) is the most frequently detected cytogenetic abnormality in patients with acute myeloid leukemia (AML) and accounts for 8-21% of de novo AML. The translocation involves two genes, RUNX1 (formerly AML1) on 21q22 and RUNX1T1 (ETO) on 8q22. RUNX1/RUNX1T1 translocation confers a favorable prognosis, but a subset of patients has a precipitous course with a high incidence of relapse. This patient subset is associated with the presence of a c-kit mutation. c-kit is a proto-oncogene, which encodes a type III transmembrane tyrosine kinase, which elicits a variety of cellular responses essential for the development of bone marrow stem cells. The expression of the c-kit mutation in AML is < 2%, whereas AML with RUNX1/RUNX1T1 shows higher rates of c-kit mutation and is associated with extramedullary leukemia and poor clinical outcome. We report cases of myeloid sarcoma in patients with RUNX1/RUNX1T1-positive AML and a c-kit mutation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Recurrence
/
Stem Cells
/
Bone Marrow
/
Protein-Tyrosine Kinases
/
Proto-Oncogenes
/
Leukemia, Myeloid, Acute
/
Leukemia
/
Oncogene Proteins, Fusion
/
Incidence
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS